Semaglutide works by stimulating the pancreas to trigger insulin production, curbing users’ appetite and contributing to feelings of fullness. Although the US Food and Drug Administration approved Ozempic to treat type 2 diabetes, doctors now commonly prescribe it off-label for weight management. About 1 in 8 adults in the US has used a GLP-1 drug, and of those, around 2 in 5 did so solely to lose weight, according to health policy non-profit KFF in 2024. The American Society of Plastic Surgeons (ASPS), which publishes an annual report on surgery trends, recently found that 2 in 5 of its members’ GLP-1 patients were considering undergoing cosmetic surgery — and 1 in 5 already had.
Read the full article: ‘Ozempic Face’ May Be Driving a Cosmetic Surgery Boom //
Source: https://edition.cnn.com/2025/07/30/style/ozempic-face-cosmetic-surgery